Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1... Pharmaceutical Investing
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy , from Bristol Myers Squibb Pharmaceutical Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma... Pharmaceutical Investing
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ?1% Pharmaceutical Investing
KEYTRUDA® Plus LENVIMA® Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma Life Science Investing
Jamieson Wellness Inc. Reports Fourth Quarter and Full Year 2021 Financial Results Life Science Investing
Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society Annual Meeting Pharmaceutical Investing
Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease Pharmaceutical Investing
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference Pharmaceutical Investing
AbbVie Announces Provincial Reimbursement for VENCLEXTA® with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia in Alberta, Saskatchewan, British Columbia, and Manitoba Pharmaceutical Investing
